Elsevier

Journal of Clinical Neuroscience

Volume 16, Issue 9, September 2009, Pages 1119-1130
Journal of Clinical Neuroscience

Review
Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas

https://doi.org/10.1016/j.jocn.2009.02.009 Get rights and content

Abstract

Angiogenesis is a key event in the progression of malignant gliomas. The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme. Tumour angiogenesis involves multiple cellular processes including endothelial cell proliferation, migration, reorganisation of extracellular matrix and tube formation. These processes are regulated by numerous pro-angiogenic and anti-angiogenic growth factors. Angiogenesis inhibitors have been developed to interrupt the angiogenic process at the growth factor, receptor tyrosine kinase and intracellular kinase levels. Other anti-angiogenic therapies alter the immune response and endogeneous angiogenesis inhibitor levels. Most anti-angiogenic therapies for malignant gliomas are in Phase I/II trials and only modest efficacies are reported for monotherapies. The greatest potential for angiogenesis inhibitors may lie in their ability to combine safely with chemotherapy and radiotherapy.

Introduction

Two distinct processes have been described for the formation of vasculature. Vasculogenesis refers to the formation of primitive blood vessels from mesoderm by differentiation of angioblasts during embryonic development.1 After the primary vascular plexus is formed, further expansion of the circulatory network relies on sprouting or splitting from pre-existing vessels in a process termed angiogenesis.[2], [3], [4], [5] Blood vessels formed in later stages of embryonic development or in adults as a result of tissue demands are predominantly products of angiogenesis.6 The formation of new blood vessels occurs physiologically during embryogenesis, the reproductive cycle in females and wound healing.[5], [7], [8] Angiogenesis also takes place in a variety of pathological states, including ischemic diseases, chronic inflammatory reactions, and cancer.[2], [9]

It was almost a century ago that the association between angiogenesis and cancer was initially observed.[10], [11], [12] In 1966, Folkman et al. first showed that tumour growth and metastasis required the formation of new blood vessels.13 Sufficient nutrients and waste exchange can be achieved by diffusion if tumour cells are situated within about 100 μm of blood vessels.[14], [15] However, growth of tumours beyond this limit necessitates the recruitment of a new blood supply and consequently leads to the emergence of an angiogenic phenotype.[3], [14] Exponential growth of tumours exceeding 1–2 mm3 occurs after a vascular network is established through angiogenesis.[10], [13], [16], [17], [18], [19], [20]

The hypothesis that tumours produced a diffusible angiogenic substance was proposed in 1968.[21], [22] Folkman et al. subsequently proposed in 1971 that tumour growth and metastasis were angiogenesis dependent, and hence, blocking angiogenesis could be a strategy to arrest tumour growth.23 In 1976, Gullino showed that cells in pre-malignant tissue acquired angiogenic capacity as part of the transformation to become fully malignant.24 Genetic studies subsequently confirmed that the acquisition of an angiogenic phenotype was one of the hallmarks of cancer.[3], [25], [26], [27], [28]

Angiogenesis is recognised as a key event in the progression of glioma.[29], [30], [31] Among all solid tumours, glioblastoma multiforme (GBM) has been reported to be the most angiogenic by displaying the highest degree of vascular proliferation and endothelial cell hyperplasia.32 Such intense vascularisation is partly responsible for the pathological features of GBM, including peritumoral oedema resulting from the defective blood brain barrier (BBB) in the newly formed tumour vasculature.[33], [34], [35], [36] These vessels are associated with increased risks of intratumoural haemorrhage[37], [38] and are also responsible for contrast enhancement on neuroimaging.[36], [39], [40], [41]

Unlike tumours in other locations, gliomas rarely metastasise to distant organs and their aggressive behaviour and poor prognosis are determined by their histological grade. Microvascular proliferation is a diagnostic criterion distinguishing low grade from high grade astrocytomas and is a histopathological hallmark of GBM.[42], [43], [44], [45], [46]

Although it is uncertain if microvascular proliferation is the cause or effect of malignant tumour behaviours, neovascularisation in gliomas correlates positively with their biological aggressiveness, degree of malignancy and clinical recurrence and inversely with the post-operative survival of patients.[43], [44], [45]

The angiogenic potential of GBM was first recognised in 1976 by observing new vessel formation elicited by GBM implanted into rabbit corneas.47 Moreover, glioma cells induced endothelial cell proliferation and tube formation in vitro.[48], [49] Angiogenic factors such as vascular endothelial growth factor (VEGF) have been identified in pseudopalisading tumour cells adjacent to necrotic zones and hyperplastic vessels, implicating their role in glioma angiogenesis.[50], [51], [52], [53], [54] Hypoxia inducible factor-1 (HIF-1)α is also expressed in pseudopalisading cells in conjunction with VEGF, which provides a link between hypoxia and angiogenesis in malignant glioma.[52], [54], [55], [56]

Section snippets

The mechanism of angiogenesis

Angiogenesis involves a sequence of coordinated events that is initiated by the expression of angiogenic factors such as VEGF with subsequent binding to its cognate receptors on endothelial cells (Fig. 1). VEGF increases vascular permeability, which leads to extravasation of plasma proteins and dissociation of pericyte coverage.[50], [53] Endothelial cell migration and proliferation then follow in preparation for the new vasculature.57 Local degradation of the vascular basement membrane and

Mediators of glioma angiogenesis

Vascular homeostasis is governed by a balance between pro-angiogenic and anti-angiogenic factors. More than 25 different growth factors and cytokines have been identified that are able to induce angiogenesis72 (Fig. 2). The production of angiogenic growth factors is either the result of genetic alterations or is induced by hypoxia.

Anti-angiogenic therapies in malignant gliomas

Strategies have been devised to inhibit angiogenesis in malignant gliomas: blocking growth factor production, neutralisation of circulating growth factors, inhibition of RTK activation and suppression of intracellular signalling cascades. Although no anti-angiogenic drug has been approved for the treatment of malignant gliomas, many have undergone Phase I/II clinical trials (Table 1, Fig. 3).

Conclusions

Tumour-related angiogenesis is a fertile ground for developing effective anti-cancer treatments. Anti-angiogenic agents have special roles in the treatment of central nervous system tumours because they can bypass the BBB in exerting their effects. In addition, GBM is one of the most angiogenic tumours in humans, thus rendering it an ideal target for anti-angiogenic treatment.32 Most angiogenesis inhibitors are not highly effective as a monotherapy. Fortunately, many of these agents are able to

Acknowledgements

We thank the Royal Australasian College Surgeons Surgeon Scientist Scholarship and the Friends of Royal Melbourne Hospital Neuroscience Foundation for their support.

References (277)

  • S. Hiratsuka et al.

    MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis

    Cancer Cell

    (2002)
  • T. Cohen et al.

    Interleukin 6 induces the expression of vascular endothelial growth factor

    J Biol Chem

    (1996)
  • P. Guo et al.

    Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment

    Am J Pathol

    (2003)
  • L. Pertovaara et al.

    Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells

    J Biol Chem

    (1994)
  • E. Berra et al.

    Signaling angiogenesis via p42/p44 MAP kinase and hypoxia

    Biochem Pharmacol

    (2000)
  • X. Na et al.

    Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas

    J Urol

    (2003)
  • W. Risau et al.

    Vasculogenesis

    Annu Rev Cell Dev Biol

    (1995)
  • J. Folkman

    Angiogenesis in cancer, vascular, rheumatoid and other disease

    Nat Med

    (1995)
  • W. Risau

    Mechanisms of angiogenesis

    Nature

    (1997)
  • G.D. Yancopoulos et al.

    Vascular-specific growth factors and blood vessel formation

    Nature

    (2000)
  • P. Carmeliet et al.

    Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

    Nature

    (1996)
  • P. Carmeliet et al.

    Angiogenesis in cancer and other diseases

    Nature

    (2000)
  • G.H. Algire et al.

    Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants

    J Natl Cancer Inst USA

    (1945)
  • E. Goldman

    The growth of malignant disease in man and the lower animals with special reference to the vascular system

    Lancet

    (1907)
  • A.G. Ide et al.

    Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber

    Am J Radiol

    (1939)
  • J. Folkman et al.

    Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment

    Ann Surg

    (1966)
  • J. Folkman

    What is the evidence that tumors are angiogenesis dependent?

    J Natl Cancer Inst

    (1990)
  • M.A. Gimbrone et al.

    Tumor growth and neovascularization: an experimental model using the rabbit cornea

    J Natl Cancer Inst

    (1974)
  • M.A. Gimbrone et al.

    Tumor dormancy in vivo by prevention of neovascularization

    J Exp Med

    (1972)
  • D. Knighton et al.

    Avascular and vascular phases of tumour growth in the chick embryo

    Br J Cancer

    (1977)
  • W.M. Lien et al.

    The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber

    Surgery

    (1970)
  • W.D. Thompson et al.

    Tumours acquire their vasculature by vessel incorporation, not vessel ingrowth

    J Pathol

    (1987)
  • R.L. Ehrmann et al.

    Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy

    J Natl Cancer Inst

    (1968)
  • M. Greenblatt et al.

    Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique

    J Natl Cancer Inst

    (1968)
  • J. Folkman

    Tumor angiogenesis: therapeutic implications

    N Engl J Med

    (1971)
  • P.M. Gullino

    Angiogenesis and oncogenesis

    J Natl Cancer Inst

    (1978)
  • K.M. Dameron et al.

    Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1

    Science

    (1994)
  • P.H. Maxwell et al.

    The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

    Nature

    (1999)
  • J. Rak et al.

    Oncogenes as inducers of tumor angiogenesis

    Cancer Metastasis Rev

    (1995)
  • O.V. Volpert et al.

    Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity

    Oncogene

    (1997)
  • L. Bello et al.

    Angiogenesis and invasion in gliomas

    Cancer Treat Res

    (2004)
  • S.Y. Cheng et al.

    Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor

    Proc Natl Acad Sci USA

    (1996)
  • D. Zagzag

    Angiogenic growth factors in neural embryogenesis and neoplasia

    Am J Pathol

    (1995)
  • S. Brem et al.

    Tumor angiogenesis: a quantitative method for histologic grading

    J Natl Cancer Inst

    (1972)
  • R.F. Del Maestro et al.

    Mechanisms of tumor-associated edema: a review

    Can J Neurol Sci

    (1990)
  • J. Vaquero et al.

    Expression of vascular permeability factor in glioblastoma specimens: correlation with tumor vascular endothelial surface and peritumoral edema

    J Neurooncol

    (2000)
  • D. Zagzag et al.

    Neovascularization and tumor growth in the rabbit brain. A model for experimental studies of angiogenesis and the blood-brain barrier

    Am J Pathol

    (1988)
  • D. Zagzag et al.

    Angiogenesis and blood-brain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain-tumor model

    AJR Am J Roentgenol

    (1989)
  • S.Y. Cheng et al.

    Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189

    Proc Natl Acad Sci USA

    (1997)
  • B.H. Liwnicz et al.

    The relationship between the capillary structure and hemorrhage in gliomas

    J Neurosurg

    (1987)
  • Cited by (103)

    • Ardisia crispa root hexane fraction suppressed angiogenesis in human umbilical vein endothelial cells (HUVECs) and in vivo zebrafish embryo model

      2019, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      Additionally, the activity of an individual protein is not solely dependent on its abundance, but also on the results of interacting, modifying, antagonistic and synergistic with other proteins [67]. For instance, FGFs could increase the VEGF level by inducing its expression or releasing stored VEGF in the ECM [68]. Both proangiogenic mediators then act synergistically to amplify new vessels sprouting [69,70].

    • Advances in the Anti-Tumor Activity of Biflavonoids in Selaginella

      2023, International Journal of Molecular Sciences
    View all citing articles on Scopus
    View full text